USP

オキサリプラチン

Name: オキサリプラチン
Brand: USP

United States Pharmacopeia (USP) Reference Standard

別名:

[SP-4-2-(1R-trans)]-(1,2-シクロヘキサンジアミン-N,N′)[エタンジオアタ(2--)-O,O′]白金

ログインで組織・契約価格をご覧ください。

サイズを選択してください

この商品について

実験式（ヒル表記法）:

C₈H₁₄N₂O₄Pt

CAS番号:

61825-94-3

分子量:

397.29

NACRES:

NA.24

PubChem Substance ID:

329750629

UNSPSC Code:

41116107

MDL number:

MFCD00866327

主要文書

すべての文書を表示

テクニカルサービス

お困りのことがあれば、経験豊富なテクニカルサービスチームがお客様をサポートします。

お手伝いします

テクニカルサービス

お困りのことがあれば、経験豊富なテクニカルサービスチームがお客様をサポートします。

お手伝いします

製品名

オキサリプラチン, United States Pharmacopeia (USP) Reference Standard

InChI

1S/C6H14N2.C2H2O4.Pt/c7-5-3-1-2-4-6(5)8;3-1(4)2(5)6;/h5-6H,1-4,7-8H2;(H,3,4)(H,5,6);/q;;+2/p-2/t5-,6-;;/m1../s1

SMILES string

O=C1O[Pt]OC1=O.N[C@@H]2CCCC[C@H]2N

InChI key

ZROHGHOFXNOHSO-BNTLRKBRSA-L

grade

pharmaceutical primary standard

API family

oxaliplatin

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

類似した製品をお探しですか？訪問製品比較ガイド

General description

この製品は薬局方標準品です。発行元の薬局方により製造・供給されています。詳しい情報は、発行元の薬局方のウェブサイトよりご確認ください。

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.

Application

Oxaliplatin USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:

Oxaliplatin Injection
Oxaliplatin for Injection

Other Notes

Sales restrictions may apply.

pictograms

GHS08,GHS05

signalword

Danger

hcodes

H317,H318,H334,H341,H351,H360FD,H362,H372

pcodes

P260 - P263 - P280 - P302 + P352 - P305 + P351 + P338 - P308 + P313

Hazard Classifications

Carc. 2 - Eye Dam. 1 - Lact. - Muta. 2 - Repr. 1B - Resp. Sens. 1B - Skin Sens. 1 - STOT RE 1

保管分類

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

適用法令

試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。

1481204-125MG:

jan

最新バージョンのいずれかを選択してください：

試験成績書（COA）

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 資料 section.

サポートが必要な場合は、お問い合わせくださいカスタマーサポート

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

Isolated hepatic perfusion with oxaliplatin combined with 100 mg melphalan in patients with metastases confined to the liver: A phase I study.

L B J van Iersel et al.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 40(11), 1557-1563 (2014-08-16)

To improve isolated hepatic perfusion (IHP), we performed a phase I dose-escalation study to determine the optimal oxaliplatin dose in combination with a fixed melphalan dose. Between June 2007 and July 2008, 11 patients, comprising of 8 colorectal cancer and

Platinum-RNA modifications following drug treatment in S. cerevisiae identified by click chemistry and enzymatic mapping.

Maire F Osborn et al.

ACS chemical biology, 9(10), 2404-2411 (2014-07-24)

With the importance of RNA-based regulatory pathways, the potential for targeting noncoding and coding RNAs by small molecule therapeutics is of great interest. Platinum(II) complexes including cisplatin (cis-diamminedichloroplatinum(II)) are widely prescribed anticancer compounds that form stable adducts on nucleic acids.

Analgesic effects of clinically used compounds in novel mouse models of polyneuropathy induced by oxaliplatin and cisplatin.

Jennifer R Deuis et al.

Neuro-oncology, 16(10), 1324-1332 (2014-04-10)

Peripheral neuropathy is the major dose-limiting side effect of cisplatin and oxaliplatin, and there are currently no effective treatments available. The aim of this study was to assess the pharmacological mechanisms underlying chemotherapy-induced neuropathy in novel animal models based on

A phase 3 non-inferiority study of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer: updated results of the FIRIS study.

Hirofumi Yasui et al.

Journal of cancer research and clinical oncology, 141(1), 153-160 (2014-08-12)

The FIRIS study previously demonstrated non-inferiority of IRIS (irinotecan plus S-1) to FOLFIRI (5-fluorouracil/leucovorin with irinotecan) for progression-free survival as the second-line chemotherapy for metastatic colorectal cancer (mCRC) as the primary endpoint. The overall survival (OS) data were immature at

Polymeric micelles loaded with platinum anticancer drugs target preangiogenic micrometastatic niches associated with inflammation.

Hailiang Wu et al.

Journal of controlled release : official journal of the Controlled Release Society, 189, 1-10 (2014-06-24)

Nanocarriers have been used for specific delivery of therapeutic agents to solid tumors based on the enhanced permeability and retention in cancerous tissues. Despite metastasis is the main reason of cancer-related death and a priority for nanocarrier-based therapies, the targeting

オキサリプラチン

United States Pharmacopeia (USP) Reference Standard

サイズを選択してください

この商品について

主要文書

特性

製品名

InChI

SMILES string

InChI key

grade

API family

manufacturer/tradename

application(s)

format

storage temp.

関連するカテゴリー

詳細

General description

Analysis Note

Application

Other Notes

安全性情報

pictograms

signalword

hcodes

pcodes

Hazard Classifications

保管分類

wgk

flash_point_f

flash_point_c

適用法令

1481204-125MG:

資料

試験成績書（COA）

以前この製品を購入いただいたことがある場合

参考文献

テクニカルサービス